MX2018013778A - Mutante cd200 y sus usos. - Google Patents
Mutante cd200 y sus usos.Info
- Publication number
- MX2018013778A MX2018013778A MX2018013778A MX2018013778A MX2018013778A MX 2018013778 A MX2018013778 A MX 2018013778A MX 2018013778 A MX2018013778 A MX 2018013778A MX 2018013778 A MX2018013778 A MX 2018013778A MX 2018013778 A MX2018013778 A MX 2018013778A
- Authority
- MX
- Mexico
- Prior art keywords
- protein
- relates
- mutant
- mutated
- mutation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La invención se refiere en general a proteínas CD200 mutantes que se unen con mayor afinidad al receptor de CD200 que la CD200 de tipo silvestre, en particular la invención se refiere a una proteína CD200 mutada que comprende una mutación en la posición del residuo de aminoácido 130 y/o 131; esta invención también se refiere a una proteína de fusión que comprende la proteína como se define en la presente fusionada a una proteína que no es CD200 que codifica una porción vía una porción enlazadora opcional, una composición farmacéutica que comprende la proteína como se define en la presente y usos de la misma.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1608197.8A GB201608197D0 (en) | 2016-05-10 | 2016-05-10 | Novel proteins |
| PCT/GB2017/051303 WO2017194941A1 (en) | 2016-05-10 | 2017-05-10 | Cd200 mutant and its uses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018013778A true MX2018013778A (es) | 2019-08-01 |
| MX386295B MX386295B (es) | 2025-03-18 |
Family
ID=56297468
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018013778A MX386295B (es) | 2016-05-10 | 2017-05-10 | Mutante cd200 y sus usos |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US11203628B2 (es) |
| EP (1) | EP3455247A1 (es) |
| JP (1) | JP6997767B2 (es) |
| KR (2) | KR102689460B1 (es) |
| CN (1) | CN109219614B (es) |
| AU (1) | AU2017264825B2 (es) |
| BR (1) | BR112018073280A2 (es) |
| CA (1) | CA3023601A1 (es) |
| EA (1) | EA201892554A1 (es) |
| GB (1) | GB201608197D0 (es) |
| IL (1) | IL262846B2 (es) |
| MX (1) | MX386295B (es) |
| NZ (1) | NZ747665A (es) |
| SG (1) | SG11201809677XA (es) |
| WO (1) | WO2017194941A1 (es) |
| ZA (1) | ZA201807079B (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201608197D0 (en) | 2016-05-10 | 2016-06-22 | Ducentis Biotherapeutics Ltd | Novel proteins |
| KR102186780B1 (ko) | 2019-02-18 | 2020-12-04 | 박주현 | 비행부와 탑승부를 분리하여 축으로 결합한 유인드론 |
| CN110859951A (zh) * | 2019-09-23 | 2020-03-06 | 中国药科大学 | Cd200蛋白和cd200融合蛋白在制备治疗银屑病药物中的应用 |
| GB202115803D0 (en) * | 2021-11-03 | 2021-12-15 | Ducentis Biotherapeutics Ltd | Novel proteins |
| EP4519298A1 (en) * | 2022-05-06 | 2025-03-12 | Ducentis Biotherapeutics Limited | Novel cd200 fusion proteins |
| JP2025516364A (ja) * | 2022-05-06 | 2025-05-27 | デュセンティス バイオセラピューティクス リミテッド | 新規ｃｄ２００融合タンパク質 |
| GB2626300A (en) * | 2022-12-08 | 2024-07-24 | Ducentis Biotherapeutics Ltd | Mutated CD200 proteins and methods of use therof |
| GB202303291D0 (en) | 2023-03-07 | 2023-04-19 | Secr Defence | Medicament and medicament combination for use in the treatment of infectious disease |
| GB202306711D0 (en) * | 2023-05-05 | 2023-06-21 | Ducentis Biotherapeutics Ltd | Novel proteins |
| WO2025106841A1 (en) * | 2023-11-15 | 2025-05-22 | The University Of Chicago | Methods and compositions for inducing antigen specific tolerance |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2260852T3 (es) | 1997-11-07 | 2006-11-01 | Trillium Therapeutics Inc. | Metodos y composiciones para inmunomodulacion. |
| US7223729B2 (en) * | 1997-11-07 | 2007-05-29 | Trillium Therapeutics Inc. | Methods of treating allergy by administering a CD200 protein |
| WO2000061171A2 (en) | 1999-04-13 | 2000-10-19 | Schering Corporation | Uses of mammalian ox2 protein and related reagents |
| WO2001066689A2 (en) | 2000-03-07 | 2001-09-13 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
| DE60135573D1 (de) * | 2000-11-22 | 2008-10-09 | Trillium Therapeutics Inc | Verkürztes cd200 |
| RU2515108C2 (ru) * | 2005-08-19 | 2014-05-10 | Эббви Инк | Иммуноглобулин с двойными вариабельными доменами и его применения |
| CA2674578A1 (en) | 2007-01-11 | 2008-07-24 | Boehringer Ingelheim International Gmbh | Cd200 and its receptor, cd200r, modulate bone mass via the differentiation of osteoclasts |
| CN102448982B (zh) * | 2009-03-31 | 2018-04-20 | 华盛顿大学 | 用于调节靶细胞上补体调节蛋白的活性的组合物和方法 |
| NZ601111A (en) * | 2010-01-11 | 2014-07-25 | Alexion Pharma Inc | Biomarkers of immunomodulatory effects in humans treated with anti-cd200 antibodies |
| GB201608197D0 (en) | 2016-05-10 | 2016-06-22 | Ducentis Biotherapeutics Ltd | Novel proteins |
-
2016
- 2016-05-10 GB GBGB1608197.8A patent/GB201608197D0/en not_active Ceased
-
2017
- 2017-05-10 WO PCT/GB2017/051303 patent/WO2017194941A1/en not_active Ceased
- 2017-05-10 KR KR1020237004504A patent/KR102689460B1/ko active Active
- 2017-05-10 US US16/300,382 patent/US11203628B2/en active Active
- 2017-05-10 CN CN201780028505.0A patent/CN109219614B/zh active Active
- 2017-05-10 CA CA3023601A patent/CA3023601A1/en active Pending
- 2017-05-10 KR KR1020187035514A patent/KR102498901B1/ko active Active
- 2017-05-10 EA EA201892554A patent/EA201892554A1/ru unknown
- 2017-05-10 EP EP17724607.1A patent/EP3455247A1/en active Pending
- 2017-05-10 NZ NZ747665A patent/NZ747665A/en unknown
- 2017-05-10 BR BR112018073280-0A patent/BR112018073280A2/pt active Search and Examination
- 2017-05-10 AU AU2017264825A patent/AU2017264825B2/en active Active
- 2017-05-10 SG SG11201809677XA patent/SG11201809677XA/en unknown
- 2017-05-10 MX MX2018013778A patent/MX386295B/es unknown
- 2017-05-10 JP JP2019511816A patent/JP6997767B2/ja active Active
-
2018
- 2018-10-24 ZA ZA2018/07079A patent/ZA201807079B/en unknown
- 2018-11-07 IL IL262846A patent/IL262846B2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017264825A1 (en) | 2018-11-15 |
| KR20230025937A (ko) | 2023-02-23 |
| CN109219614B (zh) | 2022-05-24 |
| EP3455247A1 (en) | 2019-03-20 |
| GB201608197D0 (en) | 2016-06-22 |
| JP6997767B2 (ja) | 2022-03-04 |
| CA3023601A1 (en) | 2017-11-16 |
| SG11201809677XA (en) | 2018-11-29 |
| EA201892554A1 (ru) | 2019-04-30 |
| KR102689460B1 (ko) | 2024-07-26 |
| KR102498901B1 (ko) | 2023-02-10 |
| JP2019518788A (ja) | 2019-07-04 |
| AU2017264825B2 (en) | 2021-04-08 |
| WO2017194941A1 (en) | 2017-11-16 |
| MX386295B (es) | 2025-03-18 |
| BR112018073280A2 (pt) | 2019-03-19 |
| IL262846B (en) | 2022-10-01 |
| US20190367580A1 (en) | 2019-12-05 |
| CN109219614A (zh) | 2019-01-15 |
| ZA201807079B (en) | 2019-07-31 |
| IL262846A (en) | 2018-12-31 |
| KR20190003761A (ko) | 2019-01-09 |
| IL262846B2 (en) | 2023-02-01 |
| NZ747665A (en) | 2025-10-31 |
| US11203628B2 (en) | 2021-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018013778A (es) | Mutante cd200 y sus usos. | |
| CY1124309T1 (el) | Τροποποιημενα πολυπεπτιδια fgf-21 και χρησεις εξ αυτων | |
| CY1126121T1 (el) | Πρωτεϊνες συντηξης υποδοχεα tgf-bhta τυπου ii και χρησεις aυτων | |
| DOP2018000245A (es) | Proteinas de fusion gdf15 y usos de estas | |
| ZA202409972B (en) | Fcrn antagonists and methods of use | |
| AR099288A1 (es) | Proteínas de fusión de interleucina-10 | |
| CL2019001000A1 (es) | Proteínas de fusión fc heterodiméricas il15/il15ralfa | |
| CL2013003328A1 (es) | Polipeptidos biespecíficos contra cd32 y cd16 unidos covalentemente a variantes del dominio de unión a la albumina 3 de la proteína g de estreptococo g148, que poseen una vida sérica aumentada; usos; y composiciones farmaceuticas. | |
| PE20240817A1 (es) | Mutantes de proteina f de rsv | |
| BR112016020368A2 (pt) | proteínas fc multiméricas | |
| PH12018500657A1 (en) | Optimized variants of anti-vegf antibodies | |
| EA201691111A1 (ru) | Химерные белки фактора viii и их применение | |
| UY40420A (es) | Formulación que comprende una superóxido dismutasa | |
| CU24301B1 (es) | Variantes de polipéptidos y proteínas de angiopoyetina-tipo 3 (angptl3) | |
| BR112015022208A8 (pt) | proteínas de fusão que compreendem pdgf e partes de ligação de vegf, e métodos de utilização do mesmo | |
| BR112016020377A2 (pt) | proteínas fc multiméricas | |
| EA201792466A1 (ru) | АНТИТЕЛА ПРОТИВ FcRn | |
| BR112015014727B8 (pt) | Composição imunogênica, vacina, e, uso de uma composição imunogênica | |
| CY1124110T1 (el) | Συνθεσεις και μεθοδοι μεταλλαγμενου παραγοντα viii | |
| CY1122644T1 (el) | Πρωτεϊνες συντηξης tatk-cdkl5, συνθεσεις, φαρμακοτεχνικες μορφες και η χρηση αυτων | |
| PH12017500742A1 (en) | Statherin peptides | |
| BR112019001156A2 (pt) | proteínas de fusão de fragmentos de proteína humana para criar composições de fc de imunoglobulina multimerizadas ordenadas com ligação de receptor fc reforçada | |
| FR3001729B1 (fr) | Mutants du facteur x | |
| MX374380B (es) | Composicion inmunógena de clostridium difficile. | |
| EP4031558A4 (en) | CHIMERIC HEMAGGLUTININ PROTEIN AND VACCINE COMPOSITION COMPRISING THEM |